Skip To Main Content
Khadija Rerhou on Muck Rack

Khadija Rerhou

As seen in: arXiv, Biomed Central (BMC)
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Khadija Rerhou’s profile

Articles by Khadija Rerhou

[2610.28265] Composite Variable Strategies for Continuous Endpoints

|
By Khadija Rerhou, Christian Bressen
| arXiv
arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website. Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them. Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.
Open in Who Shared View Duplicates (698) Issue with article?

Challenges and Lessons Learned in Autologous Chimeric Antigen Receptor T-Cell Therapy Development from a Statistical Perspective - Therapeutic Innovation & Regulatory Science

|
By Khadija Rerhou, Bristol Myers Squibb
| link.springer.com
Abstract Chimeric antigen receptor (CAR) T-cell therapy is a human gene therapy product where T cells from a patient are genetically modified to enable them to recognize desired target antigen(s) more effectively. In recent years, promising antitumor activity has been seen with autologous CAR T cells. Since 2017, six CAR T-cell therapies for the treatment of hematological malignancies have been approved by the Food and Drug Administration (FDA).
Open in Who Shared Issue with article?

Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study

|
By Siew Wan, Thomas R. Jeffry, Khadija Rerhou, de Bono
| gla.ac.uk
Solovyeva, O. et al. (2023) Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study. BMC Medicine, 21, 246. (doi: 10.1186/s12916-023-02937-0) Text 302304.pdf - Published Version Available under License Creative Commons Attribution. 1MB Abstract Background: Early phase dose-finding (EPDF) trials are crucial for the development of a new intervention and influence whether it should be investigated in further trials.
Open in Who Shared Issue with article?

Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study - BMC Medicine

|
By Thomas R. Jeffry, de Bono, Siew Wan, Khadija Rerhou
| Biomed Central (BMC)
Timeline and key parts of the study To drive delivery of the project, an international Executive Committee (EC) of multidisciplinary experts was formed, and an Independent Expert Panel (IEP) provided oversight and quality control assurances (see Additional file A1). Development of CONSORT-DEFINE commenced in March 2021, followed by SPIRIT-DEFINE in January 2022.
Open in Who Shared Issue with article?
Show More